Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Virtual Congress 2020

e-Poster Display Session

431P - Quantitative study of two critical lncRNAs in patients with glioma tumours

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Translational Research

Tumour Site

Central Nervous System Malignancies

Presenters

Kamal Mohammadian

Citation

Annals of Oncology (2020) 31 (suppl_6): S1407-S1415. 10.1016/annonc/annonc368

Authors

K. Mohammadian1, A. Moradi2, M. Shabani3, S. Kazemi4, S. Mohammad Ganji5

Author affiliations

  • 1 Radiation Oncology, Hamedan Universitt of Medical Sciences, 6517619657 - Hamadan/IR
  • 2 Medical Biotechnology, National institute of Genetic Engineering and Biotechnology, 6514312434 - Tehran/IR
  • 3 Genetics, Faculty of sciences, tehran Azad university, Tehran/IR
  • 4 Genetics, Tehran Azad university, Tehran/IR
  • 5 Medical Biotechnology, National institute of genetic Engineering, Tehran/IR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 431P

Background

Glioma is one of the most common types of tumor of the central nervous system with high morbidity and mortality. Based on this fact that the prognosis of patients with high- grade glioma is poor, it is very important to develop new diagnostic and therapeutic strategies covering more efficient methods and drugs. Recent studies have demonstrated that Long non-coding RNAs (lncRNAs) may act as potential inducers or suppressors of numerous types of tumors including glioma. Besides, there are more expression of lncRNAs than coding mRNAs and miRNAs in specific tissues.In this study we evaluated two lncRNAs including MEG3 and MDC1-AS1 which seemed to be involved in the initiation and progression of high grade Gliomas.

Methods

The expression of lncRNAs were studied on 150 paraffin tissue block samples of Iranian participants, including 37 samples of low-grade gliomas(I&II), 58 samples of high grade glioma (III& IV) and 95 samples of non-tumoral tissues. After RNA extraction and complementary DNA synthesis(cDNA), probe-based (Taqman) Real-time PCR were used to evaluate lncRNAs expression level followed by statistical analizing.

Results

Our analysis, indicates that lncRNAs including MEG3 and MDC-AS1 are down-regulated (p =0.001) in high grade glioma tumors (grade III & IV) in comparison to low grade gliomas (grade I and II) and non-tumoral tissues.

Conclusions

The results show that there are critical expression differences i n MEG3 and MDC1-AS1 lncRNAs as tumor suppressor genes between high and low-grade gliomas. Comprising with other reports, it could be assumed that expression of MEG3 and MDC1-AS1 lncRNAs may serve as potential biomarkers and also therapeutic targets for detection and treatment of glioma tumors. Key words: Quantitative, lncRNAs, glioma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Arash Moradi.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.